Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.
Blanco B, Ramírez-Fernández Á, Bueno C, Argemí-Muntadas L, Fuentes P, Aguilar-Sopeña Ó, Gutierrez-Agüera F, Zanetti SR, Tapia-Galisteo A, Díez-Alonso L, Segura-Tudela A, Castellà M, Marzal B, Betriu S, Harwood SL, Compte M, Lykkemark S, Erce-Llamazares A, Rubio-Pérez L, Jiménez-Reinoso A, Domínguez-Alonso C, Neves M, Morales P, Paz-Artal E, Guedan S, Sanz L, Toribio ML, Roda-Navarro P, Juan M, Menéndez P, Álvarez-Vallina L. Blanco B, et al. Among authors: gutierrez aguera f. Cancer Immunol Res. 2022 Apr 1;10(4):498-511. doi: 10.1158/2326-6066.CIR-21-0853. Cancer Immunol Res. 2022. PMID: 35362043 Free PMC article.
CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity.
Bueno C, Velasco-Hernandez T, Gutiérrez-Agüera F, Zanetti SR, Baroni ML, Sánchez-Martínez D, Molina O, Closa A, Agraz-Doblás A, Marín P, Eyras E, Varela I, Menéndez P. Bueno C, et al. Leukemia. 2019 Aug;33(8):2090-2125. doi: 10.1038/s41375-019-0418-8. Epub 2019 Feb 18. Leukemia. 2019. PMID: 30778134 Free PMC article. No abstract available.
Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia.
Sánchez-Martínez D, Baroni ML, Gutierrez-Agüera F, Roca-Ho H, Blanch-Lombarte O, González-García S, Torrebadell M, Junca J, Ramírez-Orellana M, Velasco-Hernández T, Bueno C, Fuster JL, Prado JG, Calvo J, Uzan B, Cools J, Camos M, Pflumio F, Toribio ML, Menéndez P. Sánchez-Martínez D, et al. Blood. 2019 May 23;133(21):2291-2304. doi: 10.1182/blood-2018-10-882944. Epub 2019 Feb 22. Blood. 2019. PMID: 30796021 Free PMC article.
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.
Baroni ML, Sanchez Martinez D, Gutierrez Aguera F, Roca Ho H, Castella M, Zanetti SR, Velasco Hernandez T, Diaz de la Guardia R, Castaño J, Anguita E, Vives S, Nomdedeu J, Lapillone H, Bras AE, van der Velden VHJ, Junca J, Marin P, Bataller A, Esteve J, Vick B, Jeremias I, Lopez A, Sorigue M, Bueno C, Menendez P. Baroni ML, et al. J Immunother Cancer. 2020 Jun;8(1):e000845. doi: 10.1136/jitc-2020-000845. J Immunother Cancer. 2020. PMID: 32527933 Free PMC article.
Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope.
Velasco-Hernandez T, Zanetti SR, Roca-Ho H, Gutierrez-Aguera F, Petazzi P, Sánchez-Martínez D, Molina O, Baroni ML, Fuster JL, Ballerini P, Bueno C, Fernandez-Fuentes N, Engel P, Menendez P. Velasco-Hernandez T, et al. J Immunother Cancer. 2020 Aug;8(2):e000896. doi: 10.1136/jitc-2020-000896. J Immunother Cancer. 2020. PMID: 32788237 Free PMC article.
A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL.
Zanetti SR, Velasco-Hernandez T, Gutierrez-Agüera F, Díaz VM, Romecín PA, Roca-Ho H, Sánchez-Martínez D, Tirado N, Baroni ML, Petazzi P, Torres-Ruiz R, Molina O, Bataller A, Fuster JL, Ballerini P, Juan M, Jeremias I, Bueno C, Menéndez P. Zanetti SR, et al. Among authors: gutierrez aguera f. Mol Ther. 2022 Feb 2;30(2):550-563. doi: 10.1016/j.ymthe.2021.08.033. Epub 2021 Sep 1. Mol Ther. 2022. PMID: 34478871 Free PMC article.
CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.
Bueno C, Barrera S, Bataller A, Ortiz-Maldonado V, Elliot N, O'Byrne S, Wang G, Rovira M, Gutierrez-Agüera F, Trincado JL, González-González M, Morgades M, Sorigué M, Bárcena P, Zanetti SR, Torrebadell M, Vega-Garcia N, Rives S, Mallo M, Sole F, Mead AJ, Roberts I, Thongjuea S, Psaila B, Juan M, Delgado J, Urbano-Ispizúa A, Ribera JM, Orfao A, Roy A, Menendez P. Bueno C, et al. Among authors: gutierrez aguera f. Blood. 2022 Jul 7;140(1):38-44. doi: 10.1182/blood.2021014840. Blood. 2022. PMID: 35421218 Free PMC article.
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.
Lopez-Millan B, Sanchéz-Martínez D, Roca-Ho H, Gutiérrez-Agüera F, Molina O, Diaz de la Guardia R, Torres-Ruiz R, Fuster JL, Ballerini P, Suessbier U, Nombela-Arrieta C, Bueno C, Menéndez P. Lopez-Millan B, et al. Leukemia. 2019 Jul;33(7):1557-1569. doi: 10.1038/s41375-018-0353-0. Epub 2019 Jan 11. Leukemia. 2019. PMID: 30635633 Free PMC article.
22 results